{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:52:42Z","timestamp":1785207162656,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL007227"],"award-info":[{"award-number":["5T32HL007227"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","award":["Amato Fund for Women's CV Health Research"],"award-info":[{"award-number":["Amato Fund for Women's CV Health Research"]}],"id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiovasc Risk Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12170-022-00694-y","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T06:02:41Z","timestamp":1656136961000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention"],"prefix":"10.1007","volume":"16","author":[{"given":"Sean Paul","family":"Gaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Quispe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"694_CR1","doi-asserted-by":"crossref","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022:CIR0000000000001052.","DOI":"10.1161\/CIR.0000000000001052"},{"issue":"32","key":"694_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"16","key":"694_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"ED Michos","year":"2019","unstructured":"Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557\u201367.","journal-title":"N Engl J Med"},{"key":"694_CR4","unstructured":"\u2022\u2022 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. This is the last major US cholesterol guideline released, which recommended the addition of non-statin therapy of ezetemibe and PCSK9 inhibitors if patients at very high ASCVD risk remained above an LDL-C threshold of 70 mg\/dL despite maximally tolerated statin. This 2019 publication however was before the FDA approval of bempedoic acid and inclisiran, which were not discussed."},{"issue":"24","key":"694_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"13","key":"694_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jacc.2020.08.004","volume":"76","author":"MD Shapiro","year":"2020","unstructured":"Shapiro MD, Bhatt DL. \u201cCholesterol-years\u201d for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76(13):1517\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"694_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"\u2022 Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141\u201356. This excellent state-of-the-art review outlines the rationale that LDL-C is causally linked to atherosclerotic cardiovascular disease (ASCVD) and why lower LDL-C for longer periods of time is associated with reduction in (ASCVD.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"694_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1161\/CIRCULATIONAHA.114.014433","volume":"131","author":"SS Martin","year":"2015","unstructured":"Martin SS, Michos ED. Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young. Circulation. 2015;131(5):445\u20137.","journal-title":"Circulation"},{"issue":"1","key":"694_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jacc.2019.04.047","volume":"74","author":"KM Pencina","year":"2019","unstructured":"Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED, et al. Trajectories of non-HDL cholesterol across midlife: implications for cardiovascular prevention. J Am Coll Cardiol. 2019;74(1):70\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"694_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","volume":"131","author":"AM Navar-Boggan","year":"2015","unstructured":"Navar-Boggan AM, Peterson ED, D\u2019Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131(5):451\u20138.","journal-title":"Circulation"},{"issue":"1","key":"694_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"\u2022\u2022 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. This is the last released European Society of Cardiology guideline for cholesterol management which set a recommendation for achieving both an LDL-C reduction of 50% and an LDL-C target of <55 mg\/dL for patients at very high risk.","journal-title":"Eur Heart J"},{"issue":"21","key":"694_CR12","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.jacc.2015.03.543","volume":"65","author":"PH Joshi","year":"2015","unstructured":"Joshi PH, Martin SS, Blumenthal RS. The remnants of residual risk. J Am Coll Cardiol. 2015;65(21):2276\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"694_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"694_CR14","doi-asserted-by":"crossref","unstructured":"Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005;96(9A):3K-13K; discussion 34K-5K.","DOI":"10.1016\/j.amjcard.2005.08.002"},{"issue":"25","key":"694_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"18","key":"694_CR16","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/eurjpc\/zwaa093","volume":"28","author":"SU Khan","year":"2022","unstructured":"\u2022 Khan SU, Khan MU, Virani SS, Khan MS, Khan MZ, Rashid M, et al. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(18):2001\u20139. This recent meta-analysis of 11 randomized clinical trials (over 130,000 participants) of LDL-C lowering therapies of statins, ezetimibe, and PCSK9 inhibitors showed that intensive lowering LDL-C to <70 mg\/dL was associated with greater cardiovascular benefit with safety data showing no signal for harm.","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"694_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"694_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"9976","key":"694_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Cholesterol Treatment Trialists C, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"10170","key":"694_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists C","year":"2019","unstructured":"Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315.","journal-title":"Lancet"},{"key":"694_CR21","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials. Lancet 2010;376(9753):1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"25","key":"694_CR22","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/CIRCULATIONAHA.119.044275","volume":"140","author":"ED Michos","year":"2019","unstructured":"Michos ED, Martin SS. Achievement of very low low-density lipoprotein cholesterol levels: is it time to unlearn concern for hemorrhagic stroke? Circulation. 2019;140(25):2063\u20136.","journal-title":"Circulation"},{"issue":"7","key":"694_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"694_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9. Circ Res. 2014;114(6):1022\u201336.","journal-title":"Circ Res"},{"issue":"4","key":"694_CR25","doi-asserted-by":"publisher","first-page":"e001632","DOI":"10.1161\/CIRCGENETICS.116.001632","volume":"10","author":"ST Kent","year":"2017","unstructured":"Kent ST, Rosenson RS, Avery CL, Chen Y-DI, Correa A, Cummings SR, et al. PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke. Circ Cardiovasc Genet. 2017;10(4):e001632.","journal-title":"Circ Cardiovasc Genet"},{"issue":"16","key":"694_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"key":"694_CR27","unstructured":"\u2022 Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. Jama. 2022; epub ahead of print. This recent proof of concept trial evaluating the initiation of PCSK9 inhibitors within 24 h of an acute MI showed that intensive LDL-C lowering conferred reduction in atheroma plaque volume as seen on intravascular ultrasound, providing a mechanism for the reduction in cardiovascular events seen in the PCSK9 inhibitor outcome trials."},{"issue":"8","key":"694_CR28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","volume":"138","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation. 2018;138(8):756\u201366.","journal-title":"Circulation"},{"issue":"4","key":"694_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338\u201350.","journal-title":"Circulation"},{"key":"694_CR30","doi-asserted-by":"crossref","unstructured":"Libby P. Lipoprotein (a). JACC: basic to translational science. 2016;1(6):428\u201331.","DOI":"10.1016\/j.jacbts.2016.08.007"},{"key":"694_CR31","doi-asserted-by":"crossref","unstructured":"\u2022 O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392. This secondary analysis of the FOURIER trial showed that evolocumab, a PCSK9 inhibitor, lowered LP(a) levels and that individuals with higher LP(a) derived greater benefit from PCSK9 inhibitor in terms of reduction in vascular events.","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"issue":"4","key":"694_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"G Reyes-Soffer","year":"2017","unstructured":"Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135(4):352\u201362.","journal-title":"Circulation"},{"issue":"15","key":"694_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"16","key":"694_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"\u2022\u2022 Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. These two pivotal phase 3 trials demonstrated that inclisiran dosed subcutaneously twice-yearly conferred a 50% reduction in LDL-C with good safety data; this work supported the recent FDA approval of inclisiran for LDL-C lowering in patients with ASCVD and heterozygous familial hypercholesterolemia.","journal-title":"N Engl J Med"},{"issue":"11","key":"694_CR35","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1093\/cvr\/cvaa212","volume":"116","author":"AJ Cupido","year":"2020","unstructured":"Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovasc Res. 2020;116(11):e136\u20139.","journal-title":"Cardiovasc Res"},{"key":"694_CR36","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.2147\/DDDT.S251865","volume":"15","author":"A Agarwala","year":"2021","unstructured":"Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther. 2021;15:1955\u201363.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"694_CR37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"694_CR38","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"694_CR39","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"694_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"\u2022 Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603. This trial showed that the combination of bemepodic acid and ezetimibe lowered LDL-C better than either agent alone, with a placebo-corrected difference of 38%, similar to what can be achieved by moderate to high-intensity statins.","journal-title":"Eur J Prev Cardiol"},{"key":"694_CR41","doi-asserted-by":"crossref","unstructured":"Khan SU, Michos ED. Bempedoic acid and ezetimibe - better together. Eur J Prev Cardiol. 2019:2047487319864672.","DOI":"10.1177\/2047487319864672"},{"issue":"11","key":"694_CR42","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","volume":"78","author":"W Zhang","year":"2021","unstructured":"Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a). J Am Coll Cardiol. 2021;78(11):1083\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"694_CR43","unstructured":"\u2022 Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM, Jr., Laufs U, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022, epub ahead of print. This pooled post hoc analysis of trial data showed that, unlike statins, bempedoic acid does not worsen glycemia or increase the risk for new-onset diabetes."},{"issue":"12","key":"694_CR44","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","volume":"181","author":"IA Mansi","year":"2021","unstructured":"Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562\u201374.","journal-title":"JAMA Intern Med"},{"key":"694_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","volume":"235","author":"S Nicholls","year":"2021","unstructured":"Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104\u201312.","journal-title":"Am Heart J"},{"issue":"5","key":"694_CR46","doi-asserted-by":"publisher","first-page":"e205202","DOI":"10.1001\/jamanetworkopen.2020.5202","volume":"3","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MZ, Raghu Subramanian C, Riaz H, Khan MU, Lone AN, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. 2020;3(5):e205202.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"694_CR47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","volume":"32","author":"D Noto","year":"2012","unstructured":"Noto D, Cefal\u00f9 AB, Valenti V, Fayer F, Pinotti E, Ditta M, et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler Thromb Vasc Biol. 2012;32(3):805\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"694_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrcardio.2017.91","volume":"14","author":"GB Lim","year":"2017","unstructured":"Lim GB. ANGPTL3: a therapeutic target for atherosclerosis. Nat Rev Cardiol. 2017;14(7):381.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"694_CR49","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308\u201317.","journal-title":"J Lipid Res"},{"key":"694_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","volume":"277","author":"FJ Raal","year":"2018","unstructured":"Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483\u201392.","journal-title":"Atherosclerosis"},{"issue":"10","key":"694_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discovery. 2020;19(10):673\u201394.","journal-title":"Nat Rev Drug Discovery"},{"key":"694_CR52","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Liang X-H, Baker BF, Crooke RM. Antisense technology: a review. J Biol Chem. 2021;296:100416.","journal-title":"J Biol Chem"},{"issue":"18","key":"694_CR53","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377\u201386.","journal-title":"Circulation"},{"key":"694_CR54","unstructured":"Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-topline-results-phase-2b-trial-vupanorsen [Accessed March 12, 2022]. 2021."},{"key":"694_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/JEP.S267376","volume":"13","author":"I Pe\u0107in","year":"2021","unstructured":"Pe\u0107in I, Reiner \u017d. Novel experimental agents for the treatment of hypercholesterolemia. J Exp Pharmacol. 2021;13:91\u2013100.","journal-title":"J Exp Pharmacol"},{"issue":"12","key":"694_CR56","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","volume":"77","author":"S Tsimikas","year":"2021","unstructured":"Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2\/4. J Am Coll Cardiol. 2021;77(12):1576\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"694_CR57","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"22","key":"694_CR58","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331.","journal-title":"JAMA"},{"issue":"16","key":"694_CR59","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","volume":"79","author":"P Mohammadi-Shemirani","year":"2022","unstructured":"Mohammadi-Shemirani P, Chong M, Narula S, Perrot N, Conen D, Roberts JD, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and Mendelian randomization study. J Am Coll Cardiol. 2022;79(16):1579\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"694_CR60","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","volume":"50","author":"Y Pan","year":"2019","unstructured":"Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and alzheimer disease: a Mendelian randomization study. Stroke. 2019;50(12):3532\u20139.","journal-title":"Stroke"},{"issue":"1","key":"694_CR61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","volume":"4","author":"PR Kamstrup","year":"2016","unstructured":"Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart failure. 2016;4(1):78\u201387.","journal-title":"JACC Heart failure"},{"issue":"3","key":"694_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"\u2022 Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. Important phase 2 trial showing that pelacarsen can lower Lp(a) in a dose-dependent manner up to 80%. This work set the stage for the ongoing HORIZON cardiovascular outcome trial with pelacarsen.","journal-title":"N Engl J Med"},{"issue":"11","key":"694_CR63","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"694_CR64","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327(17):1679\u201387.","journal-title":"JAMA"},{"key":"694_CR65","doi-asserted-by":"crossref","unstructured":"Koren MJ, Moriarty PM, Neutel J, Baum SJ, Hernandez-Illas M, Weintraub HS, et al. Abstract 13951: safety, tolerability and efficacy of single-dose Amg 890, a novel siRNA targeting Lp(a), in healthy subjects and subjects with elevated Lp(a). Circulation 2020;142(Suppl_3):A13951-A.","DOI":"10.1161\/circ.142.suppl_3.13951"},{"issue":"1","key":"694_CR66","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911.","journal-title":"Nat Commun"},{"issue":"7859","key":"694_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"},{"key":"694_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.athplu.2021.08.003","volume":"43","author":"KK Ray","year":"2021","unstructured":"Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL, et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe \u2013 methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus. 2021;43:24\u201330.","journal-title":"Atherosclerosis Plus"},{"issue":"9","key":"694_CR69","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"\u2022 Cannon CP, De Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiology. 2021;6(9):1060. Registry data of US patients with ASCVD showing two-thirds of patients remained suboptimally treated with LDL-C above the goal of 70 mg\/dL and only 17% had their lipid-lowering therapy intensified over a 2-year period.","journal-title":"JAMA Cardiology"},{"issue":"1","key":"694_CR70","first-page":"eaj_22005","volume":"1","author":"ED Michos","year":"2022","unstructured":"Michos ED, Ferdinand KC. Lipid-lowering for the prevention of cardiovascular disease in the new era: a practical approach to combination therapy. Eur Atheroscler J. 2022;1(1):eaj_22005.","journal-title":"Eur Atheroscler J"}],"container-title":["Current Cardiovascular Risk Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12170-022-00694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12170-022-00694-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12170-022-00694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T08:27:58Z","timestamp":1660984078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12170-022-00694-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s12170-022-00694-y","relation":{},"ISSN":["1932-9520","1932-9563"],"issn-type":[{"value":"1932-9520","type":"print"},{"value":"1932-9563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"18 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Michos has served on advisory boards for AstraZeneca, Amarin, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}